Destiny Pharma (LON:DEST) posted its quarterly earnings data on Tuesday. The company reported GBX (11.90) (($0.16)) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (16.20) (($0.21)) by GBX 4.30 ($0.06), Digital Look Earnings reports.

LON DEST remained flat at $GBX 84 ($1.10) on Thursday. 3,935 shares of the company’s stock were exchanged, compared to its average volume of 4,205. Destiny Pharma has a twelve month low of GBX 61 ($0.80) and a twelve month high of GBX 131.40 ($1.72). The company has a market capitalization of $36.48 million and a PE ratio of -7.92.

Separately, FinnCap reiterated a “corporate” rating on shares of Destiny Pharma in a research report on Tuesday.

COPYRIGHT VIOLATION WARNING: “Destiny Pharma (DEST) Releases Quarterly Earnings Results, Beats Estimates By $4.30 EPS” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at

Destiny Pharma Company Profile

Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.

Further Reading: What does relative strength index mean?

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with's FREE daily email newsletter.